Burning Rock Biotech Ltd
NASDAQ:BNR
Intrinsic Value
The intrinsic value of one BNR stock under the Base Case scenario is 6.77 USD. Compared to the current market price of 2.9 USD, Burning Rock Biotech Ltd is Undervalued by 57%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
BNR Profitability Score
Profitability Due Diligence
Burning Rock Biotech Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Burning Rock Biotech Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
BNR Solvency Score
Solvency Due Diligence
Burning Rock Biotech Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Burning Rock Biotech Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Burning Rock Biotech Ltd
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 1B |
| Receivables | 149M |
| Other Current Assets | 196M |
| Non-Current Assets | 377M |
| Long-Term Investments | 644k |
| PP&E | 347M |
| Intangibles | 2.8M |
| Other Non-Current Assets | 26.4M |
| Current Liabilities | 363M |
| Accounts Payable | 71M |
| Accrued Liabilities | 121M |
| Other Current Liabilities | 171M |
| Non-Current Liabilities | 68.9M |
| Other Non-Current Liabilities | 68.9M |
BNR Capital Structure
Burning Rock Biotech Ltd
| Market Capitalization | 305M USD | |
| Total Debt | 0 USD | |
| Minority Interest | 0 USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 1B USD | |
| Short-Term Investments | 0 USD | |
| Enterprise Value | -705M USD | |
Wall St
Price Targets
BNR Price Targets Summary
Burning Rock Biotech Ltd
According to Wall Street analysts, the average 1-year price target for BNR is 6.95 USD with a low forecast of 3.84 USD and a high forecast of 11.34 USD.
Shareholder Return
BNR Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
BNR Price
Burning Rock Biotech Ltd
| Average Annual Return | -29.45% |
| Standard Deviation of Annual Returns | 40.61% |
| Max Drawdown | -96% |
| Market Capitalization | 305M USD |
| Shares Outstanding | 105 725 500 |
| Percentage of Shares Shorted | 5.22% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one BNR stock under the Base Case scenario is 6.77 USD.
Compared to the current market price of 2.9 USD, Burning Rock Biotech Ltd is Undervalued by 57%.
